{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:08:41Z","timestamp":1792069721616,"version":"4.4.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is a rare, aggressive and incurable subtype of non-Hodgkin\u2019s B-cell lymphoma. The principal barrier is frequent clinical relapse to multiple lines of therapies, including new FDA-approved biologics and cell therapy. Brexucabtagene autoleucel, the first and only FDA approved chimeric antigen receptor (CAR) T product in MCL, demonstrated unprecedented efficacy in overcoming resistance to Bruton\u2019s tyrosine kinase inhibitors. However, relapses have inevitably occurred and once relapsed these patients display a very poor clinical outcome. Currently, there is no optional therapy specifically designed for these patients. The development of tailored and more efficacious therapies is therefore critical and represents a new medical need. We found that while the receptor tyrosine kinase-like orphan receptor 1 (ROR1) is expressed across most of the MCL cells, it is significantly elevated in CAR T-relapsed MCL tumors. To see whether this aberrant ROR1 expression contributed to CAR T resistance, we targeted ROR1 using VLS-101, a monomethyl auristatin E conjugated anti-ROR1 antibody. VLS-101 showed potent anti-MCL activity in vitro in ROR1-expressing MCL cell lines and ex vivo in primary patient samples. Importantly, VLS-101 safely induced tumor regression in PDX models resistant to CAR T-cell therapy, ibrutinib and\/or venetoclax. These data advocate for targeting ROR1 as a viable approach in the treatment of ROR1-positive MCL tumors, especially those with failure to prior therapies. These data also provide strong evidence for future enrollment of post-CD19 CAR T-cell relapsed MCL patients in a first in-human phase 1b VLS-101 trial. The upcoming testing in a clinical setting will provide important insights on this new therapeutic development aiming to overcome the CAR T resistance via targeting ROR1, which is a rising unmet clinical need in MCL.<\/jats:p>","DOI":"10.1186\/s13045-021-01143-w","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T08:02:46Z","timestamp":1630137766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma"],"prefix":"10.1186","volume":"14","author":[{"given":"Vivian Changying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katti A.","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lannutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"1143_CR1","doi-asserted-by":"crossref","unstructured":"Jiang, V.C. et al. Targeting ROR1 using the antibody drug conjugate Vls-101 in aggressive mantle cell lymphoma. Blood. 2020;136","DOI":"10.1182\/blood-2020-137660"},{"key":"1143_CR2","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"MH Wang","year":"2020","unstructured":"Wang MH, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New Engl J Med. 2020;382:1331\u201342.","journal-title":"New Engl J Med"},{"key":"1143_CR3","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1111\/bjh.17197","volume":"192","author":"P Jain","year":"2021","unstructured":"Jain P, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Brit J Haematol. 2021;192:E38\u201342.","journal-title":"Brit J Haematol"},{"key":"1143_CR4","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan A, et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res. 2017;23:3061\u201371.","journal-title":"Clin Cancer Res"},{"key":"1143_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","volume":"181","author":"S Zhang","year":"2012","unstructured":"Zhang S, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012;181:1903\u201310.","journal-title":"Am J Pathol"},{"key":"1143_CR6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1073\/pnas.1816262116","volume":"116","author":"SP Zhang","year":"2019","unstructured":"Zhang SP, et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci USA. 2019;116:1370\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1143_CR7","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","volume":"128","author":"B Cui","year":"2016","unstructured":"Cui B, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128:2931\u201340.","journal-title":"Blood"},{"key":"1143_CR8","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","volume":"203","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, et al. Cutting edge: ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor-BTK signaling pathway. J Immunol. 2019;203:2043\u20138.","journal-title":"J Immunol"},{"key":"1143_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood.V130.Suppl_1.829.829","volume":"130","author":"M Choi","year":"2017","unstructured":"Choi M, et al. Durable and specific inhibition of ROR1 signaling associates with prolonged progression free survival in patients with chronic lymphocytic leukemia treated with cirmtuzumab. Blood. 2017;130:829.","journal-title":"Blood"},{"key":"1143_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","volume":"22","author":"MY Choi","year":"2018","unstructured":"Choi MY, et al. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell. 2018;22:951-959 e953.","journal-title":"Cell Stem Cell"},{"key":"1143_CR11","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2019-126827","volume":"134","author":"T Vaisitti","year":"2019","unstructured":"Vaisitti T, et al. Vls-101 is a novel therapeutic antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in Richter\u2019s syndrome (RS). Blood. 2019;134:2856.","journal-title":"Blood"},{"key":"1143_CR12","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1182\/blood.2020008404","volume":"137","author":"T Vaisitti","year":"2021","unstructured":"Vaisitti T, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021;137:3365\u201377.","journal-title":"Blood"},{"key":"1143_CR13","first-page":"13","volume":"136","author":"M Wang","year":"2020","unstructured":"Wang M, et al. VLS-101, a ROR1-targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical efficacy in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma. Blood. 2020;136:13\u20134.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01143-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01143-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01143-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T20:07:55Z","timestamp":1630181275000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01143-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01143-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient samples were collected from peripheral blood, bone marrow, or apheresis after obtaining informed consent and approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center. All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.W. has a grant from VelosBio Inc., and philanthropy from Steve and Nancy Fox Cancer Research Fund. K.A.J., and B.J.L., are fulltime employed by VelosBio Inc. All other authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}],"article-number":"132"}}